Physician profile
Steven Ventrudo
NPI 1265432736
$517.38
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $517.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $82.29 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $68.08 | 2019 | |
| Novo Nordisk INC | $50.35 | 2019 | |
| Sanofi-Aventis U.S. LLC | $38.81 | 2019 | |
| Glaxosmithkline, LLC. | $31.06 | 2019 | |
| Sanofi Pasteur INC. | $27.93 | 2019 | |
| Lundbeck LLC | $25.96 | 2019 | |
| Mylan Specialty L.P. | $18.44 | 2019 | |
| Ge Healthcare | $17.45 | 2019 | |
| Merck Sharp & Dohme LLC | $17.40 | 2019 | |
| Pfizer INC. | $15.70 | 2019 | |
| Amarin Pharma, INC. | $15.69 | 2019 | |
| Biodelivery Sciences International, INC. | $15.50 | 2019 | |
| Radius Health, INC. | $14.73 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.97 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $13.95 | 2019 | |
| Amgen INC. | $13.08 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $12.45 | 2019 | |
| Allergan, INC. | $12.41 | 2019 | |
| Circassia INC. | $12.13 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Ventrudo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.